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Abstract 
Background: We reviewed the current medical literature that pertained to the question 
of whether myocardial ischemia triggers the release of B-type natriuretic peptides 
(BNPs) and, in particular, whether transient exercise-induced ischemia can be detected 
by the measurement of changes in these biomarkers. BNPs are well-established as 
markers of left ventricular dysfunction, particularly heart failure. There is accumulating 
evidence that various conditions with the common denominator of myocardial ischemia 
are also associated with increased circulating levels of these peptides. 
 
Methods and Results: Recently published methods and results, which includes our 
published and unpublished data, were reviewed. 
 
Conclusion: The results show that exercise-induced ischemia or its associated regional 
wall-motion abnormalities trigger the release of BNPs and that the measurement of 
plasma levels of N-terminal pro brain natriuretic peptide and BNP before and immediately 
after symptom-limited exercise can distinguish patients with and without ischemia with a 
high degree of accuracy. 
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Noninvasive diagnosis of coronary artery disease is based primarily on the demonstration of inducible 
myocardial ischemia. Exercise electrocardiography, which for many years has been the standard 
diagnostic test for this purpose, has only modest sensitivity and specificity for the detection of coronary 
stenosis, compared with coronary angiography.1 The addition of radionuclide myocardial perfusion 
imaging or echocardiography to exercise or pharmacologic stress has improved the diagnostic accuracy 
of these procedures, although with a significant increase in cost and technologic complexity. 
Various other imaging techniques, such as electron-beam computed tomography and multi-
detector spiral computed tomography, show promise in the detection of coronary atherosclerotic 
plaque, although the appropriate clinical applications of these technologies remain to be determined. At 
present, only functional studies (such as exercise or pharmacologic stress tests) or invasive studies 
(such as intracoronary measurement of fractional flow reserve) are able to assess the hemodynamic 
significance of stenotic lesions (ie, whether a lesion is sufficient to prevent adequate increase in 
myocardial perfusion under increased metabolic demand). 
A large meta-analysis of studies of the accuracy of exercise testing for the detection of 
significant (50%–70%) coronary stenosis at subsequent cardiac angiography found a mean sensitivity 
and specificity of 68% and 70%, respectively.1 However, all studies that were included in this analysis 
were affected by work-up bias, which tends to overestimate sensitivity, because false-negative tests are 
less likely to be detected. A subsequent study with reduced work-up bias found a sensitivity and 
specificity of 45% and 85%, respectively.2 Recent studies that used the demonstration of reversible 
defects on radionuclide imaging, rather than coronary anatomy, as the reference standard for ischemia 
have found significantly lower sensitivities (range, 36%–45.5%) for the exercise electrocardiogram 
than had been reported previously.3-5 It may be argued that this method (i.e., the demonstration of 
reversible perfusion defects on myocardial imaging) is actually a better reference standard for ischemia 
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than angiographically demonstrated coronary stenosis, because stenosis may be present in the absence 
of ischemia and ischemia may be present in the absence of the stenosis. In addition, it is ischemia, not 
coronary stenosis per se, that is presumed to produce reversible abnormalities on the exercise 
electrocardiogram. Thus, in summary, there is accumulating evidence that the sensitivity of the 
exercise electrocardiogram for the detection of ischemia is considerably lower than has generally been 
believed. 
The natriuretic peptides are a family of chemically related neurohormones that are produced 
predominantly in the heart. Biochemical details of these compounds have been described elsewhere. It 
has been well-established that levels of these peptides are elevated in circumstances of volume or 
pressure overload of the ventricle (for example, congestive heart failure) 6-8; the triggering mechanism 
is believed to be an increase in wall stress with accompanying myocyte stretch that leads to BNP gene 
transcription by way of a p38 mitogen-activated protein kinase mechanism.9 
 
B-Type Natriuretic Peptides (BNPs) as Biomarkers of Ischemia 
Experimental and In Vitro Evidence 
In 1994, Toth et al10 demonstrated that hypoxia increases BNP secretion in isolated rat myocardium, 
which provided the first evidence that stimuli other than increased wall stress might trigger BNP 
release. More recently, D'Souza et al,11 who used isolated perfused rat hearts, found that BNP 
concentrations in coronary effluent during reperfusion correlated with the duration of induced 
myocardial ischemia. Of particular interest was the finding that short periods of ischemia (2–5 minutes) 
were not associated with rises in end-diastolic pressure, which suggests that ischemia per se, rather than 
increases in wall stress as the result of ischemia, triggers BNP release. This study also confirmed the 
very rapid release of BNP from ischemic myocardium. Goetze et al12-13 have demonstrated 
subsequently in a porcine model that the induction of myocardial ischemia in hearts with normal 
ventricular function results in a rapid and significant rise in BNP gene expression in the affected tissues 
and in isolated perfused ventricular myocytes that are incubated in a hypoxic medium. 
 
Clinical Evidence 
In the clinical setting, various investigations have now shown elevations of BNP and N-terminal pro-
brain natriuretic peptide (NT-proBNP) in a number of other pathologic conditions in the absence of 
overt left ventricular failure; among these conditions are myocardial infarction,14-15 unstable angina,16-18 
diastolic dysfunction,19-20 and percutaneous coronary angioplasty.21- 22 Of note, Tateishi et al22 observed 
that coronary angiography alone, without balloon angioplasty, did not result in elevations of BNP; a 
plausible explanation for this observation is that vessel occlusion by balloon inflation during 
angioplasty produces transient tissue ischemia, whereas angiography alone does not. 
Few studies have examined the effect of exercise on cardiac markers in plasma. Four studies 
examined the effect of single episodes of exercise on BNP levels 23- 26; of these, 2 studies included 
patients with coronary artery disease (CAD) and data on nuclear perfusion imaging.25-26 Although there 
was a trend toward increases in BNP in patients compared with normal control subjects, the studies 
were limited by small sample sizes, unmatched control subjects, submaximal work loads and peak 
heart rates, and a lack of documentation of ischemia. 
Our laboratory recently performed a study to test the hypothesis that transient, exercise-
induced ischemia would trigger the release of BNP and NT-proBNP, either directly or through the 
induction of regional wall motion abnormalities, and that increases in these peptides after exercise 
might be a marker of ischemia.27 We studied 21 healthy volunteers and 74 patients with known CAD 
(most of whom were diagnosed by coronary angiography), normal left ventricular function, and normal 
resting levels of NT-proBNP and BNP who were referred for exercise testing with radionuclide 
imaging. Resting and post-exercise blood samples (<1, 10, 30, and 60 minutes after exercise) were 
analyzed in batches for NT-proBNP, with the Roche electrochemiluminescent immunoassay on an 
Elecsys 1010 autoanalyzer, the Shionogi radioimmunoassay, and the Biosite fluorescent point-of-care 
BNP immunoassay. The following data were coefficients of variation for the assays: NT-proBNP, 
1.3%–2.4%; BNP, 11.2%–14.6%.28 
All patients and volunteers underwent symptom-limited exercise testing; the CAD patient 
group also underwent concurrent radionuclide single photon emission computed tomography (SPECT) 
imaging. Patients with CAD were divided into 2 groups, ischemic (n = 40) and nonischemic (n = 34), 
on the basis of the presence or absence of inducible ischemia on radionuclide imaging. 
Volunteer blood was analyzed for NT-proBNP only, and pre-exercise (baseline) levels were 
within normal limits for all subjects. In the ischemic and nonischemic patient groups, although baseline 
Journal of Cardiac Failure (2005) 11 (5) Supplement 1: 59-64.                  http://dx.doi.org/10.1016/j.cardfail.2005.04.021 
levels of NT-proBNP and BNP were within normal limits, median levels of both peptides were 
significantly higher in the ischemic group (NT-proBNP, 120.5 pg/mL vs 53.5 pg/mL; P < .0001; BNP, 
40.5 pg/mL vs 16.5 pg/mL; P < .001). Interquartile ranges showed no overlap in NT-proBNP values 
and only modest overlap in BNP values. Resting NT-proBNP values were lower in the healthy 
volunteers (median, 25 pg/mL) than in the CAD patient groups (P = .0053 vs nonischemic group), 
which is consistent with their much younger age.27 
A comparison of the incremental rise of NT-proBNP (∆NT-proBNP) between patients with 
and without reversible ischemia at 1, 10, 30, and 60 minutes after exercise showed that maximal ∆NT-
proBNP was already observed at 1 minute after exercise (Fig. 1; unpublished data). This difference in 
∆NT-proBNP is statistically significant. To address the contribution of previous myocardial infarction 
to the exercise-induced increases in the peptides, a subset analysis of the ischemic patients without 
fixed defects on nuclear images was conducted and found that neither resting nor post-exercise levels 
differed significantly from the ischemic group as a whole.  
 
 
Fig. 1. Kinetics of ∆NT-proBNP in patients with (circles) and without (squares) reversible ischemia. 
 
At approximately 1 minute after exercise, the median ∆NT-proBNP in the healthy volunteers and 
nonischemic patients was not statistically significant (5 pg/mL vs 4 pg/mL; P = not significant; Fig. 
2).27 However, the ∆NT-proBNP and ∆BNP in the ischemic patient group were significantly higher 
than in the nonischemic patient group (∆NT-proBNP, 14.5 pg/mL vs 4 pg/mL [P < .0001]; ∆BNP, 36.5 
pg/mL vs 7.5 pg/mL [P < .0001]; Fig. 2).27 As with resting levels, there was no overlap in the 
interquartile ranges for NT- proBNP and modest overlap for BNP. 
 
 
 
 
Fig. 2. (A) Changes in NT proBNP and (B) BNP in nonischemic and ischemic subjects. Ranges, 
medians and 25th–75th percentiles are shown. Reproduced from reference 27 with permission from 
American College of Cardiology Foundation. 
 
To evaluate the ability of ∆NT-proBNP and ∆BNP levels to predict the presence or absence of 
ischemia in individual patients, we constructed receiver operator characteristic curves for each peptide 
(Fig. 3; unpublished data) for a subset of 72 patients. The area under the receiver operator characteristic 
curve assesses the overall accuracy of each assay's ability to detect ischemia; for ∆NT-proBNP, it was 
0.806 (95% CI, 0.705–0.907); for Biosite, the ∆BNP was 0.685 (95% CI, 0.559–0.810), and for 
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Shionogi radioimmunoassay, the ∆BNP was 0.654 (95% CI, 0.525–0.783). Although there was a trend 
towards higher area under the receiver operator characteristic curve for ∆NT-proBNP compared with 
∆BNP for the detection of ischemia, the differences were not statistically significant in this subset of 72 
patients. 
 
 
Fig. 3. Comparison of receiver-operator characteristic curve for changes in Shionogi RIA ∆BNP 
(diamonds), Biosite Triage ∆BNP (squares), and Roche Elecsys ∆NT-proBNP (triangles) in a subset 
of 72 subjects. 
 
An analysis of the complete series of 74 patients demonstrated that at equivalent specificity of 58.8%, 
∆NT-proBNP >5 pg/mL showed 2.4-fold higher sensitivity, and ∆BNP >10 pg/mL showed 2.1-fold 
higher sensitivity, when compared with ≥1 mm ST depression on electrocardiography. Thus, a ∆NT-
proBNP of >5 pg/mL or ∆BNP of >10 pg/mL is associated with an increased positive likelihood ratio 
of approximately 2.0 for ischemia in patients who undergo exercise-stress testing (Table 1).27 
 
TABLE 1.  
Test Characteristics of Roche ∆NT-ProBNP,* Biosite Triage ∆BNP,† and Electrocardiogram  
   Predictive Value (%)  Likelihood Ratio 
Variable Sensitivity (%) 
Specificity 
(%) Positive Negative
Diagnostic 
Accuracy 
(%) 
Positive Negative
∆NT-proBNP >5 
pg/mL 90.0 58.8 72.0 83.3 75.7 2.19 0.17 
∆BNP >10 pg/mL 80.0 58.8 69.6 71.4 70.3 1.94 0.34 
≥1-mm ST 
depression on 
electrocardiogram 
37.5 58.8 51.7 44.4 47.3 0.91 1.06 
 
Reproduced from reference 27 with permission from American College of Cardiology Foundation. 
* Change after exercise in N-terminal fragment of brain natriuretic peptide pro-hormone. 
† Change after exercise in brain natriuretic peptide (carboxy-terminal active fragment). 
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To assess the association of ∆NT-proBNP and ∆BNP with the extent and severity of ischemia, we 
examined the relationship of the delta peptide levels with sum difference scores (SDS), the computer 
analysis of perfusion images that assesses both size and severity of reversible defects. We found a 
strong correlation between the delta peptide levels and SDS scores (Pearson r = 0.33; P = .004), which 
suggests that the greater the extent and severity of ischemia, the greater the rise in BNP levels. Results 
of this analysis are shown in Figure 4 (unpublished data). 
 
Fig. 4. Correlation of SDS with ∆NT-proBNP (circles) and ∆BNP (squares). 
Our findings suggested that exercise-induced ischemia results in detectable increases in levels of B-
type natriuretic peptides.27 Although we cannot exclude the possibility that the immediate proximate 
trigger is ischemia-induced regional wall motion abnormalities, all patients in our study had normal 
resting left-ventricular function, and other evidence cited earlier, particularly the in vitro studies of 
isolated myocardial cells, suggests that the trigger may be ischemia per se. Of particular note is that the 
median absolute ∆NT-proBNP in the nonischemic patient group was almost identical to that of the 
healthy volunteers, despite marked differences in age, exercise capacity, maximal heart rates, and 
resting NT-proBNP levels in the nonischemic patients that were more than twice as high as those of the 
volunteers. On the other hand, an unexpected finding revealed that median levels of both NT-proBNP 
(120.5 vs 53.5 pg/mL) and BNP (40.5 vs 16.5 pg/mL) were significantly higher at rest in the group of 
patients with inducible ischemia than in the group without.27 If, as our findings suggest, ischemia 
triggers the release of these natriuretic peptides, patients with ischemia on scans may have higher 
baseline levels of NT-proBNP and BNP because of chronic or recurrent episodes of ischemia before 
testing. 
Corroborative Studies 
Since completion of our study, several other investigators have found similar associations between 
levels of NT- proBNP and/or BNP and inducible ischemia. Bibbins-Domingo et al29 measured resting 
levels of BNP in 355 patients with stable CAD who underwent subsequent exercise treadmill testing 
with exercise echocardiography. Of this group, 113 patients (32%) had inducible ischemia. Those 
patients in the highest quartile of resting levels (≥105 pg/mL) had double the risk of having ischemia 
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(relative risk, 2.0; 95% CI, 1.20–2.6; P = .008) compared with those in the lowest quartile (≤16.4 
pg/mL). Of interest was that the association between resting BNP and inducible ischemia in this study 
group held only for patients with a history of previous myocardial infarction. Asada et al30 studied 317 
patients who were undergoing dobutamine stress echocardiography and measured BNP levels before 
and immediately after dobutamine stress. Thirty-one of their patients (10%) had ischemia and the risk 
of ischemia that was correlated with increasing tertiles of resting BNP levels (4%, 9%, and 16%, 
respectively; chi-squared test for trend = 8; P = .0059); interestingly, changes in BNP with dobutamine 
stress were not associated with ischemia. Palumbo et al31 measured BNP levels at rest in 4 groups: 
(group A) patients with stable angina and normal 201Thallium SPECT stress imaging, (group B) 
patients with exertional angina and reversible defects on imaging, (group C) patients with fixed defects 
on imaging, and (group D) normal volunteers. Left ventricular ejection fractions were not different 
among the 4 groups. Compared with the normal volunteers, BNP levels increased progressively in 
groups A, B, and C, with the highest levels in group C, which suggests that both ischemia and 
infarction are associated with elevations in resting BNP levels. Weber et al32 measured NT-proBNP at 
rest and at 15 minutes after exercise in patients who were undergoing 201Thallium SPECT stress 
imaging and subsequent coronary angiography. They found significantly increased NT-proBNP levels 
in patients with either reversible defects on imaging or with significant coronary stenosis on 
angiography. Furthermore, there was a significant correlation (Spearman r = 0.418; P < .01) between 
the peptide levels and the extent of ischemia on imaging, which was measured as a percentage of total 
myocardium. In addition, resting NT-proBNP levels were linked strongly to the severity of coronary 
disease: Median levels were 148 pg/mL, 269 pg/mL, and 624 pg/mL in patients with no CAD or 1/2- or 
3-vessel CAD (P < .001). They found no significant differences between groups in the change in BNP 
at 15 minutes after exercise compared with the resting level. Interestingly, the kinetics that we observed 
in our study (Fig. 1) would suggest that a sample drawn at this time interval might fail to detect the 
increase in peptide levels that are seen immediately after exercise. Sabatine et al,33 in a study similar to 
ours, looked at natriuretic peptide levels in 112 patients who were undergoing exercise testing with 
nuclear perfusion imaging. BNP and NT-proBNP were measured before, immediately after, and 4 
hours after exercise. These investigators found, as did we, that baseline level and after exercise level 
increases in both peptides were associated strongly with the presence of ischemia on nuclear perfusion 
imaging. They further subdivided patients into groups with no ischemia, mild to moderate ischemia, 
and severe ischemia and found baseline levels of 43, 62, and 101 pg/mL, respectively, for BNP and 
109, 158, and 302 pg/mL, respectively, for NT-proBNP for the 3 groups. All results were statistically 
significant. Examining immediate post-exercise samples, they found that the incremental rise also was 
associated strongly with ischemia and, like baseline levels, was correlated with the severity of ischemia 
on nuclear imaging. Interestingly, they found that the increases in BNP were relatively larger than the 
increases in NT-proBNP, a finding which may be related to the different expression, storage, release, 
and half-lives of the 2 compounds. These relationships held true when patients with reduced left 
ventricular function were excluded. 
 
Conclusions and Implications for Further Study 
In summary, both experimental and clinical studies have provided considerable evidence to date that 
myocardial ischemia, even for brief periods such as those induced by exercise, causes the increased 
expression and secretion of the BNPs by ventricular myocytes. This increase appears to be independent 
of global left ventricular function. Our findings and those of a number of other investigators, who used 
the model of exercise-induced ischemia, suggest that ischemia triggers the release of BNPs and that the 
measurement of plasma levels of NT-proBNP and BNP before and immediately after symptom-limited 
exercise can distinguish patients with and without ischemia with a high degree of accuracy. Studies are 
underway currently to elucidate further the nature and magnitude of these changes in different 
populations, and to assess their usefulness as an aid to the diagnosis of CAD. 
If the hypothesis that ischemia triggers BNP and NT-proBNP release is substantiated, these 
compounds then become, by definition, biomarkers of ischemia. The implications of this may be quite 
profound. As is well-known, serum markers for CAD currently are limited to markers of risk (eg, 
serum lipids and C-reactive protein) or markers of myocardial injury (eg, cardiac troponins I and T). 
Neither of these groups are true biomarkers of ischemia per se and thus do not assist, for example, in 
the differential diagnosis of patients with chest pain, unless myocardial injury began to occur at least 2 
to 6 hours before clinical evaluation. On the other hand, as ischemic biomarkers, the BNPs have several 
attributes that may enhance their usefulness as clinical tools: (1) They appear to be released in the 
presence of ischemia, even if it is insufficient to cause injury; (2) the release kinetics are very rapid, as 
demonstrated by the increases seen immediately after exercise in patients with ischemia; (3) they can 
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be measured accurately and quickly by assays with low coefficients of variation; and (4) these assays 
can be run either at the bedside or on autoanalyzers and are relatively inexpensive. Currently, there is 
no other biomarker of ischemia with these desirable characteristics. 
Further research is needed to assess the role of these peptides in the evaluation of patients with 
known or potential cardiac disease. At present, the intraindividual biologic variability of these 
compounds is characterized incompletely, as is the variability of normal levels across age, gender, and 
different degrees of renal function. In addition, it is clear that levels rise in the setting of other forms of 
cardiac pathologic conditions, notably left ventricular dysfunction, and in other non-cardiac conditions 
(eg, subarachnoid hemorrhage); thus, sorting out the contribution of ischemia to elevated levels in 
many settings will be challenging. Despite these limitations, the establishment of a link between 
myocardial ischemia per se and increases in the levels of the BNPs offer new opportunities to improve 
our ability to recognize CAD in both its acute and chronic stages.  
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